| Variable |
| Renalof® Group N = 120 | Placebo Group N = 35 | P value |
|
|
| n (%) | n (%) |
|
| Kidney Stone Recurrence | First recurrence | 78 (65.0) | 7 (20.0) | <0.001 |
| More than once | 42 (35.0) | 28 (80.0) | ||
| Previous comorbidities | No | 82 (68.3) | 12 (34.29) | <0.001 |
| Yes | 38 (31.7) | 23 (65.71) | ||
| Size of the kidney stones | Ø < 5 mm | 67 (55.83) | 18 (51.43) | 0.175 |
| 5 > Ø < 7 mm | 35 (29.17) | 15 (42.86) | ||
| 8 > Ø < 9 mm | 18 (15.00) | 2 (5.71) | ||
| Existence of kidney damage | Yes | 28 (23.3) | 1 (2.86) | 0.006 |
| No | 92 (76.6) | 34 (97.14) | ||
| Composition of kidney stones | Calcium-based | 65 (54.17) | 26 (75.00) | 0.040 |
| Uric acid-based | 32 (26.67) | 9 (25.00) | ||
| Mixed origin | 23 (19.16) | 0 (0.00) | ||
| Previous metabolic disorders | Yes | 39 (32.4) | 5 (85.7) | 0.006 |
| No | 81 (67.6) | 39 (14.3) | ||
| Type of Metabolic Alterationa | Hyperuricemia | 35 (29.0) | 4 (11.4) | 0.210 |
| Hypercalcemia | 3 (2.5) | 1 (2.9) | ||
| Hypermagnesemia | 1 (0.8) | 0 (0.0) | ||
| Serum Creatinine Levels (ng/dl) | <1.4 | 102 (85.00) | 33 (94.29) | 0.264 |
| 1.4 - 3.0 | 17 (14.10) | 2b (5.71) | ||
| >3.0 | 1 (0.90) | 0 (0.00) |